Medicamen Biotech Ltd vs Sudeep Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Medicamen Biotech Ltd is ₹ 280.1 as of 05 May 15:30 . The P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 yearsThe P/E Ratio of Sudeep Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 yearsThe Market Cap of Sudeep Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The revenue of Sudeep Pharma Ltd for the Dec '25 is ₹ 179.17 crore as compare to the Sep '25 revenue of ₹ 172.83 crore. This represent the growth of 3.67% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The ebitda of Sudeep Pharma Ltd for the Dec '25 is ₹ 66.81 crore as compare to the Sep '25 ebitda of ₹ 65.63 crore. This represent the growth of 1.8% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The net profit of Sudeep Pharma Ltd changed from ₹ 17.08 crore to ₹ 47.7 crore over 7 quarters. This represents a CAGR of 79.84% The Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 yearsThe Dividend Payout of Sudeep Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About Sudeep Pharma Ltd

Sudeep Pharma Limited was incorporated as Sudeep Pharma Private Limited' as a private limited company dated December 21, 1989, issued by the Registrar of Companies, Ahmedabad.
Thereafter, Company was converted into a public limited company and the name of the Company was changed to Sudeep Pharma Limited' pursuant to fresh certificate of incorporation dated April 5, 1995, issued by the Assistant Registrar of Companies, Gujarat at Dadra & Nagar Haveli.
Company was subsequently converted back to a private limited company vide a fresh certificate of incorporation dated October 1, 2014 issued by the Assistant Registrar of Companies, Gujarat at Ahmedabad, and the name of Company was accordingly changed from Sudeep Pharma Limited' to Sudeep Pharma Private Limited'.
Further, Company was converted into a public limited company and consequently, the name of Company was changed to Sudeep Pharma Limited'.

FAQs for the comparison of Medicamen Biotech Ltd and Sudeep Pharma Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or Sudeep Pharma Ltd?

Market cap of Medicamen Biotech Ltd is 379 Cr while Market cap of Sudeep Pharma Ltd is 7,747 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and Sudeep Pharma Ltd?

The stock performance of Medicamen Biotech Ltd and Sudeep Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and Sudeep Pharma Ltd?

As of May 5, 2026, the Medicamen Biotech Ltd stock price is INR ₹280.1. On the other hand, Sudeep Pharma Ltd stock price is INR ₹685.9.

How do dividend payouts of Medicamen Biotech Ltd and Sudeep Pharma Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and Sudeep Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.